Martin Lange

Martin Holst Lange is Executive Vice President, Development, Novo Nordisk A/S. He previously served as Senior Vice President, Global Development and Corporate Project Vice President for Insulins & Diabetes Outcomes and Insulin & Devices 2013–2017.

Dr. Lange graduated as an MD in 1997 and did 5 years of clinical work, 3 of which were at the Department of Endocrinology, National University Hospital, Denmark, where he completed a Ph.D. in Endocrinology. He joined Novo Nordisk in 2002, working with growth hormone, GLP-2, and oral anti-diabetics. He worked for 2 years at Novo Nordisk Inc. in the USA as Senior Medical Director and in 2008, moved back to Denmark to serve as Vice President, Medical & Science liraglutide during its submission and approval phase, transferring in 2010 to work in a similar capacity with insulin degludec.